- Home
- DTCX vs CPIX Comparison
DTCX vs CPIX Comparison
Compare DTCX & CPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DTCX | CPIX |
|---|---|---|
| Founded | N/A | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.0M | 59.5M |
| IPO Year | N/A | 2009 |
Fundamental Metrics
Financial Performance| Metric | DTCX | CPIX |
|---|---|---|
| Price | $2.16 | $3.80 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 575.6K | 230.6K |
| Earning Date | 02-22-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,278,349.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 12.21 |
| 52 Week Low | $1.51 | $1.85 |
| 52 Week High | $4.99 | $7.25 |
Technical Indicators
Market Signals| Indicator | DTCX | CPIX |
|---|---|---|
| Relative Strength Index (RSI) | 45.67 | 47.43 |
| Support Level | $1.81 | $3.54 |
| Resistance Level | $2.30 | $3.98 |
| Average True Range (ATR) | 0.35 | 0.34 |
| MACD | 0.03 | -0.07 |
| Stochastic Oscillator | 40.80 | 22.73 |
Price Performance
Historical ComparisonAbout DTCX Datacentrex Inc. Common Stock
Datacentrex Inc maintains a digital asset treasury composed of assets generated through its mining hashrate, including Dogecoin (DOGE), Litecoin (LTC), and Bitcoin (BTC).
About CPIX Cumberland Pharmaceuticals Inc.
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.